Dr. Reddy’s stated on that its API production plant in Bollaram, Hyderabad (CTO-3) had passed the US Food and Drug Administration’s (USFDA) GMP (good manufacturing practices) inspection with zero observations. The inspection took place from June 12 to June 16, 2023. In addition, the business announced that it has received the establishment inspection report (EIR) for its formulations manufacturing unit in Srikakulam (FTO SEZ PU2), Andhra Pradesh.
The inspection was classified as Voluntary Action Indicated (VAI) by the Agency, and the business declared it “closed” in a stock exchange announcement. The successful completion of the GMP inspection will allow Dr. Reddy’s to introduce a new product while mitigating the impact of pricing.
More About Dr. Reddy’s
Dr. Reddy’s Laboratories, commonly known as Dr. Reddy’s, is a global pharmaceutical company based in India. It was founded in 1984 by Dr. Anji Reddy, a visionary entrepreneur and philanthropist. The company is headquartered in Hyderabad, Telangana, and is one of the largest pharmaceutical manufacturers in India.
Dr. Reddy’s focuses on developing, manufacturing, and marketing a wide range of generic pharmaceuticals and active pharmaceutical ingredients (APIs) across various therapeutic areas. It has a presence in over 100 countries and operates through three business segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.
The Global Generics segment of Dr. Reddy’s is responsible for the development, manufacturing, and marketing of generic formulations in various dosage forms, such as tablets, capsules, injectables, and more. The PSAI segment focuses on the production and sale of APIs and intermediates. The Proprietary Products segment is involved in the research, development, and marketing of innovative and differentiated pharmaceutical products.
Dr. Reddy’s has a strong focus on research and development (R&D) to drive innovation and develop new products. The company has several R&D centers and facilities dedicated to drug discovery and development, formulation development, and analytical research.
Over the years, Dr. Reddy’s has received numerous accolades and recognition for its contributions to the pharmaceutical industry. It has a diverse product portfolio and is known for its affordable and high-quality medicines, which have made a significant impact on improving global healthcare access.
Please note that while I strive to provide accurate and up-to-date information, my knowledge cutoff is in September 2021, and there may have been developments or changes regarding Dr. Reddy’s Laboratories since then.
About Publisher
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here
For more Pharma related updates Click here
